Literature DB >> 18339143

Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?

Josh Levitsky1, Alison G Freifeld, Susan Puumala, Kim Bargenquast, Penny Hardiman, Catherine Gebhart, Lucy Wrenshall, Alan Langnas, Andre C Kalil.   

Abstract

Consistent data for using CMV quantitative PCR (QnPCR) on initial presentation to predict outcomes after solid organ transplantation (SOT) are lacking. Recipients with measurable CMV QnPCR and either CMV-V (asymptomatic viremia) or CMV-D (symptomatic CMV infection) were analyzed over 24 months. Risk factors and outcomes were evaluated in relation to initial QnPCR by regression analysis and time-to-event curves. Twenty-eight recipients were identified: five CMV-V, 23 CMV-D. Patients with CMV-D had a higher median initial QnPCR (230 000 copies/mL) compared with CMV-V (2500 copies/mL; p < 0.05). No patients with CMV-V had an initial QnPCR > 10 000 copies/mL compared with 83% of the CMV-D (p = 0.004). The initial QnPCR was higher (250 000 copies/mL) in patients who did not clear CMV PCR than those who cleared (8000 copies/mL) after 14 d of treatment (p = 0.03). Risk factors and indirect CMV effects were not associated with initial QnPCR. Our results highlight the importance of the initial CMV QnPCR in relation to the development of symptomatic CMV and a slower response to therapy. Alternatively, late asymptomatic viremia and recurrent CMV are associated with lower PCR levels and a low likelihood to progress and result in clinical disease.

Entities:  

Mesh:

Year:  2008        PMID: 18339143     DOI: 10.1111/j.1399-0012.2007.00778.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  5 in total

Review 1.  Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.

Authors:  Raymund R Razonable; Randall T Hayden
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

2.  A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.

Authors:  Chethan M Puttarajappa; Sundaram Hariharan; Kenneth J Smith
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-12       Impact factor: 8.237

3.  Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.

Authors:  Fernando Valenzuela; Kim A Papp; David Pariser; Stephen K Tyring; Robert Wolk; Marjorie Buonanno; Jeff Wang; Huaming Tan; Hernan Valdez
Journal:  BMC Dermatol       Date:  2015-05-08

Review 4.  Cytomegalovirus infection in transplant recipients.

Authors:  Luiz Sergio Azevedo; Lígia Camera Pierrotti; Edson Abdala; Silvia Figueiredo Costa; Tânia Mara Varejão Strabelli; Silvia Vidal Campos; Jéssica Fernandes Ramos; Acram Zahredine Abdul Latif; Nadia Litvinov; Natalya Zaidan Maluf; Helio Hehl Caiaffa Filho; Claudio Sergio Pannuti; Marta Heloisa Lopes; Vera Aparecida dos Santos; Camila da Cruz Gouveia Linardi; Maria Aparecida Shikanai Yasuda; Heloisa Helena de Sousa Marques
Journal:  Clinics (Sao Paulo)       Date:  2015-07-01       Impact factor: 2.365

5.  Cytomegalovirus viral load kinetics in patients with HIV/AIDS admitted to a medical intensive care unit: a case for pre-emptive therapy.

Authors:  Simnikiwe H Mayaphi; Marieke Brauer; Daniel M Morobadi; Ahmad H Mazanderani; Rendani T Mafuyeka; Steve A S Olorunju; Gregory R Tintinger; Anton Stoltz
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.